ADC Therapeutics (ADCT) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Company overview and product focus

• Specializes in antibody-drug conjugates with commercial-stage product Zynlonta approved for third-line plus DLBCL and a novel solid tumor portfolio using exatecan payload.

• Zynlonta is a single-agent therapy with strong efficacy (48% ORR, 25% CR) and a favorable safety profile, lacking irreversible toxicities and severe side effects seen in other treatments.

• Outpatient administration is straightforward, with a 30-minute infusion, making it accessible across care settings.

Commercial performance and growth outlook

• Achieved $69 million in sales last year, with peak potential in the current indication estimated at $80 million+.

• Maintained market volume despite increased competition from bispecifics, which now hold about a third of the third-line plus market.

• Commercially profitable, with sales exceeding commercial and medical affairs spend.

Clinical development and data highlights

• Phase 2 studies in indolent lymphomas (follicular and marginal zone) show high CR rates (80% in high-risk follicular, 75% in marginal zone) and durable responses.

• Plans to enroll 100 patients in follicular lymphoma study and pursue regulatory and guideline inclusion based on results.

• Safety profile in both monotherapy and combination regimens remains consistent and manageable.